BACKGROUND. For developing targeted immunotherapy against ovarian adenocarcinoma, direct identification of peptides presented by major histocompatibility complex class I (HLA I) on the surface of tumor cells can be utilized. However, standard immunopeptidomics protocols may vary substantially in the...
ORGANISM(S): Homo sapiens (Human)